Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clinical Trial Results
Biotech
Roche drops obesity antibody after flunked interim analysis
Trouble first started brewing back in March, when emugrobart failed to boost muscle growth in trials for two rare genetic diseases.
Darren Incorvaia
Sep 28, 2026 11:03am
Amgen fusion protein eases Sjögren's severity in ph. 3 win
Sep 22, 2026 10:20am
Novartis Lp(a) drug fails closely watched ph. 3 trial
Sep 4, 2026 9:18pm
Teva autoimmune antibody notches ph. 2 win in celiac disease
Sep 2, 2026 10:52am
BioNTech, Genentech cancel ph. 2 test of personalized cancer vax
Aug 28, 2026 1:50pm
Double shot of Vistagen’s anxiety nasal spray misses in ph. 2
Aug 6, 2026 10:32am
